AMD AI: Growth Trajectory Meets China Hurdles
AMD's Q3 revenue outlook is strong, but China AI chip sales face uncertainty as licenses are under review.
NOTRELOAD AI
Novo Nordisk Navigates US Market Headwinds & Leadership Shift
Novo Nordisk faces slowing growth, fierce competition from Eli Lilly and copycats in the US, prompting a CEO change and strategic refocus.
Yum! Brands Q2 Challenges & Strategic Response
Yum! Brands missed Q2 targets due to rising costs and soft demand. Taco Bell slowed, KFC/Pizza Hut saw declines. Value deals and AI are key strategies.
SERB Acquires Y-mAbs: Rare Oncology Expansion
SERB Pharmaceuticals acquires Y-mAbs for $412M, gaining DANYELZA, an FDA-approved treatment for high-risk neuroblastoma, enhancing rare oncology portfolio.
Pfizer's Profit Outlook Rises Amidst Strong Q2 Performance
Pfizer boosts its 2025 profit forecast due to ongoing cost reductions and strong second-quarter sales driven by top-performing drugs.
Caterpillar Q2 2025: Profit Miss, Tariffs Hit
Caterpillar's Q2 2025 adjusted earnings of $4.72/share missed estimates due to price declines & tariffs. Full-year tariff impact expected up to $1.5B. Demand remains resilient.